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Background: Depression is a chronic illness that generally requires lifelong therapy. Repetitive transcranial
magnetic stimulation (rTMS) is a noninvasive technique with few side effects that has been reported to be useful in
the treatment of depression. However, no studies to date have evaluated in a randomized controlled trial (RCT) the
efficacy of rTMS for maintenance treatment of depression.
Methods/design: In this article, we report the design and protocol of a randomized, single-blind, placebo-
controlled, parallel-group, multicenter study in China to evaluate the efficacy of rTMS in the prevention of relapse of
depressive symptoms. In total, 540 patients, aged 18 to 60 years, diagnosed with depression and experiencing an
acute exacerbation of depressive symptoms, will be enrolled. The study will consist of four phases: a screening/
tolerability phase of up to 7 days; an open-label, flexible-dose lead-in phase of 8 weeks; an open-label, fixed-dose
stabilization phase of 6 weeks; and a single-blind relapse prevention phase of 12 months. During the open-label
phase, all patients will be treated with venlafaxine. Remitters with Hamilton Rating Scale for Depression (HAM-D17)
score ≤7 will be eligible to enter the single-blind phase and will be randomly assigned to one of three groups:
group 1 on active rTMS and venlafaxine; group 2 on sham rTMS and venlafaxine; and group 3 on venlafaxine alone.
Efficacy will be evaluated during the study using relapse assessment (time between subject randomization to
treatment and the first occurrence of relapse). Secondary outcome measures will include: symptom changes,
measured by the HAM-D17; illness severity changes, measured by the Clinical Global Impression of Severity for
Depression (CGI-S-DEP); and changes in subject functioning, assessed with the Personal and Social Performance
(PSP)scale. Safety will be assessed throughout the study by monitoring of adverse events, clinical laboratory tests,
electrocardiography (ECG), and measurements of vital signs (temperature, pulse, and blood pressure) and weight.
Suicidality will be assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).
Discussion: The result of this trial will assess the efficacy of rTMS in the prevention of relapse of symptoms of
depression by determining whether rTMS in combination with an antidepressant is more efficacious than the
antidepressant alone for maintenance of the clinical response.
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Keywords: Repetitive transcranial magnetic stimulation (rTMS), Depression, Relapse* Correspondence: tanqingr@fmmu.edu.cn
1Department of Psychiatry, Xijing Hospital, The Fourth Military Medical
University, 15 Changle Road, 710032, Xi’an, China
Full list of author information is available at the end of the article
© 2013 Wang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Wang et al. Trials 2013, 14:338 Page 2 of 5
http://www.trialsjournal.com/content/14/1/338Background
Major depressive disorder (MDD) is a chronic disorder
characterized by recurrent episodes. Although there are
an ever-increasing number of antidepressants available
to clinicians, most of these do not produce immediate
beneficial actions, and adverse effects are common during
the early phases of treatment [1]. Furthermore, approxi-
mately 30% of patients are treatment-resistant. Therefore,
biological treatments, including repetitive transcranial
magnetic stimulation (rTMS) and electroconvulsive
therapy (ECT), are considered additional options for the
management of MDD.
rTMS is a noninvasive technology that uses a pulsed
electromagnetic field to modulate neuronal activity in
the cortex of the brain [2], and there is growing evidence
that it has antidepressant actions. According to most
clinical studies and meta-analyses, highfrequency rTMS is
more effective than a sham control in the treatment of
MDD in the acute stage and during partial remission [3,4].
Some studies have even reported that the efficacy of rTMS
and the longitudinal outcomes of rTMS-treated patients
are at least as good as those obtained with ECT [5-7].
Due to the recurrent nature of MDD, a crucial part of
the treatment and management of depression is the preven-
tion of these recurrences. However, there are only limited
data examining the possibility that rTMS can maintain an
antidepressant therapeutic effect. Li et al. have described
seven adults with bipolar depression who responded acutely
to rTMS, and were then treated weekly with rTMS for up
to 1 year; the results suggested that rTMS could potentially
be used as an adjunctive maintenance treatment for at least
some patients with bipolar depression [8]. Abraham and
O’Brien reported the case of a 45-year-old woman with a
longstanding history of treatment-resistant depression, who
had responded well to maintenance rTMS given weekly or
biweekly for 4 months [9]. O’Reardon et al. applied rTMS
to ten adults with MDD, with treatment periods ranging
from 6 months to 6 years, and session frequencies aver-
aging 1 to 2 per week; this open-label study suggested that
maintenance rTMS may be a safe and effective treatment
modality for some patients with unipolar depression [10].
However, all of these reports are limited by their open-label
nature and small sample size. Clearly, much work is
yet to be done in refining the rTMS parameters (intensity,
frequency, pattern, and duration) and the optimal strategy
for maintenance treatment. Therefore, sham controlled
studies are needed to evaluate the effects of maintenance
rTMS in the management of depression.
In view of this, we have designed this randomized,
controlled, multicenter study to assess the efficacy and
safety of rTMS for delaying the time to relapse in Chinese
subjects with MDD. We aim to verify whether rTMS can be
a clinically important therapy to prevent MDD recurrence
and hence improve the quality of life of patients with MDD.Methods/design
Overview
This is a multicenter, randomized, placebo-controlled,
single-blind, parallel-group study (Figure 1). This study has
been approved by the Ethical Committee of Xijing Hospital,
Xian, China, and is registered with the ClinicalTrials.
gov database (reference number: NCT01516931). The
study will be conducted according to the Declaration




In total, 540 subjects aged 18 to 60 years, meeting the
criteria for depression defined in the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(DSM-IV), and experiencing an acute exacerbation of
depression symptoms, having a baseline score of at least
14 points on the 17-item Hamilton Rating Scale for
Depression (HAM-D17) will be enrolled. Each subject will
be asked to spend 8 days as an inpatient at the beginning
of the study; willing to and capable of completing the
necessary questionnaires; able to take oral medications
independently, or have the help and support to do so for
the entire length of the study; able to return to the clinical
research site for frequent study visits; and considered
physically healthy according to screening procedures
(including physical examination, electrocardiography
(ECG), and clinical laboratory investigations).
Exclusion criteria
Patients with any of the following will be excluded:
ferromagnetic metallic implants; pacemakers; previous
neurosurgery; or a history of seizures, major head trauma,
alcoholism, drug addiction, any psychiatric or neurological
disorder other than depression and anxiety, psychotic
depression, and suicidal propensities.
Study process
The main part of the study includes run-in, stabilization,
and single-blind phases. The efficacy of rTMS, compared
with venlafaxine and placebo, in delaying the time to
relapse of symptoms of depression will be evaluated in
the single-blind phase, after initial symptom stabilization
in the run-in/stabilization phases (Figure 1).
Subjects (inpatients or outpatients) will be evaluated
for study eligibility based on prospectively defined inclusion
and exclusion criteria during a screening phase of up
to 14 days, during which all patients will be washed
out from their medications and put on venlafaxine.
Limited dose of benzodiazepine (BDZ) will be allowed.
The washout period may be shortened to allow a subject
to enter the run-in phase as soon as the day after the start
of the washout period.
Figure 1 Flow chart to illustrate the design of the trial. Enrolment and randomization of the participants, and the follow-up process are shown.
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will be treated with an open-label, flexible-dose of
venlafaxine (a relatively new antidepressant with demon-
strated efficacy, which is already in widespread clinical use
[11-13]), administered once daily in a dose range of 75 to
225 mg to identify a dose that will achieve control of
the subject’s acute symptoms. Only subjects capable
of maintaining a stable dose regimen in the last week
of this phase, and who also meet criteria of responder
(a 50% reduction in the HAM-D17 score from baseline at
two consecutive visits, and a score ≤12 at the last valid
visit prior to the stabilization phase) will be eligible to
enter the stabilization phase.
During the 6-week stabilization phase, subjects will
continue to receive the fixed dose of venlafaxine
established at the end of the run-in phase, and the
dosage of venlafaxine cannot be adjusted. Evaluation
visits will occur every 2 weeks. Subjects who maintain a
stable dose regimen (dose unchanged) during this phase
and meet criteria of remission (a HAM-D17 score ≤7)
will be eligible to be randomly assigned to the single-blind
phase of the study.
Subjects who complete the run-in and stabilization
phases of the study and who meet prospectively defined
criteria will be randomly assigned, according to permuted
block design with a fixed block, in a 1:1:1 ratio, to one of
three groups: group 1 on active rTMS and venlafaxine;
group 2 on sham rTMS and venlafaxine; and group 3 on
venlafaxine alone, where responders will be maintained on
the same effective dose of venlafaxine for the entire
duration of the randomized controlled trial (RCT), unless
they relapse and will have to exit the protocol and enter a
naturalistic follow-up. Subjects will be treated until theymeet either prospectively defined criteria for relapse
(HAM-D17>12, reduction in the HAM-D17 score ≤50%
from baseline, and meeting DSM-IV criteria for a diagnosis
of MDD) or predefined study conclusion criteria.
Interventions
For rTMS, a 100mm figure-of-eight-shaped coil and
a MagPro Compact stimulator (Dantec Company,
Copenhagen, Denmark) will be used. The resting
motor threshold (RMT) will be recorded daily, and
defined as the intensity required to elicit at least five motor
evoked potentials (MEPs) of 50 μV peak-to-peak amplitude
in ten consecutive stimulations, when the coil is placed
over the left primary motor cortex (the site for stimulation
will be 5 cm anterior to, and in the same parasagittal plane
as, the site for maximal stimulation of the abductor
pollicisbrevis). The parameters used for rTMS delivery will
be: 90% of RMT; 10 Hz; 5 minutes; 6 seconds per
train; 24 seconds inter-train interval; 1,200 pulses per
day. In maintenance phase, each participant will
receive two sessions per week for 4 weeks (1 month),
followed by two sessions every 2 weeks for the next 4
weeks (1 month), and then two sessions per month
for 10 months.
Sham stimulation will be given at the same site and
frequency, using a Magstim sham-coil system (Whitland,
UK). During rTMS, participants will be instructed to
keep their eyes open and relax.
All subjects will be given general counseling by
appropriately trained and experienced doctors once per
month. A ‘best guess’ questionnaire will be given to the
patients at the end of the study, to assess whether they
were blinded to the intervention applied.
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The primary efficacy criterion will be the time to first
relapse during the single-blind phase. Secondary efficacy
criteria will include: a reduction in the HAM-D17 score;
an improvement of global clinical status assessed by the
Clinical Global Impression of Severity for Depression
(CGI-S-DEP); and a change in subject functioning
determined by the Personal and Social Performance (PSP)
scale. Suicidality will be assessed by the Columbia Suicide
Severity Rating Scale (C-SSRS). An independent evaluator,
separated from the treatment team, will administer
rating scales.
Statistical analysis
Relapse will be estimated by the Kaplan–Meier method.
Time to relapse will be summarized (number of events,
number of censored subjects, median, and 25th and 75th
percentile of time to events) and treatment differences will
be compared using a two-sided log-rank test. The estimate
of the hazards ratio and its 95% confidence interval
will be based on the Cox proportional hazards model
with treatment as the only covariate. Secondary efficacy
variables will include the HAM-D17, CGI-S-DEP, and PSP
scores. The overall significance level across treatment
groups for all secondary analyses will be 0.05 (two-sided)
with no multiplicity adjustments.
Discussion
MDD is a condition that is difficult-to-treat, and is predicted
to rank second on the list of 15 major diseases in terms of
burden in 2030 [14], largely due to its highly recurrent
nature. The characteristics of the treatment process for
depression include acute phase treatment, a consolidation
treatment period, and maintenance therapy. Inadequate
treatment will result in recurrence; therefore, clinicians
must be prepared to manage relapse and recurrence
aggressively throughout all phases of treatment. However,
even if antidepressant medication therapy is strictly
followed, many individuals with depression still suffer
from recurrence.
rTMS has been approved as an effective add-on therapy
for MDD [15,16], and is known as one of ‘the four
brain science technologies of the 21st century’ along
with functional magnetic resonance imaging (fMRI),
positron emission tomography (PET), and magnetoenceph-
alography (MEG). rTMS has a favorable tolerability
profile, and was approved by the US Food and Drug
Administration (FDA) in 2008, and by the European
Union (EU) in 2012, for the treatment of patients
with medication-refractory unipolar depression. At present,
in ClinicalTrials.gov, there are 102 clinical studies
worldwide assessing the use of rTMS in depression.
However, most of these are focusing on acute phase and
consolidation treatment, with only a small minority ofstudies investigating rTMS use for maintenance treatment
and recurrence prevention in depression.
Although some research has indicated that rTMS may
be effective in the prevention of MDD recurrence, these
conclusions are preliminary, with most descriptions of
the maintenance effects of rTMS being case reports that
are limited by their short-term nature. For example, a
case series suggested beneficial effects in 8 of 11 patients
with refractory depression, who maintained responder
status over a period of 3 months with rTMS therapy [9].
A recent study conducted by Janicack et al. examined
the persistence of rTMS effects in a 24-week follow-up,
and suggested that the therapeutic effects of TMS were
durable, and that TMS may be successfully used as an
intermittent rescue strategy to preclude impending relapse
[17]. Their work describes the results of a clinically plaus-
ible, effective, and safe strategy for maintenance of acute
benefit in clinical practice, and provides a framework for
the design of future controlled trials assessing rTMS for
maintenance or relapse prevention. However, rTMS
was not applied in the maintenance phase of MDD in
their study. Thus, we aim to use a RCT with a larger sam-
ple size to investigate if the rTMS treatment paradigm
shows potential as an add-on treatment to antidepressant
monotherapy for relapse prevention, and whether it might
serve a useful future role as an option for maintenance
treatment.
We expect to complete recruitment by December
2013, and anticipate that the results from this study will
not only have implications for healthcare resourcing, but
also facilitate improvements in the treatment of patients
with depression. The results of this study will also allow us
to determine if rTMS is an effective add-on intervention to
antidepressants in the maintenance stage of MDD. These
results may have important implications for the relief of the
disease burden caused by MDD relapse.
Randomization and a single-blind design will be used
in this trial to ensure adequate concealment. To date,
this trial is one of the largest RCTs assessing the efficacy
of rTMS for maintenance treatment of MDD. The trial
is still in the recruitment phase.
Trial status
Patient recruitment is still ongoing.
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